Shenzhen Hepalink Pharma, China’s major heparin API company, will invest $60 million in TPG Biotechnology Partners V. Two years ago, Hepalink put $22 million in TPG Biotechnology Partners IV. TPG, a US-headquartered firm known primarily as a PE specialist, invests in all stages of development in its biotech fund. It will pursue global opportunities in therapeutics, medical devices and healthcare services.
